Follow us on Twitter
This page is updated frequently with new Autoimmune-related patent applications. Subscribe to the Autoimmune RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune RSS
National Center For Child Health And Development
Immune tolerance inducer
Method for treating b cell regulated autoimmune disorders
|| List of recent Autoimmune-related patents
| Ptprs and proteoglycans in autoimmune disease|
Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology
| Humanized antibodies to cluster of differentiation 3 (cd3)|
Humanized monoclonal antibodies (mabs) or fragments thereof, to human cluster of differentiation 3 (cd3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mabs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to cd3, are also disclosed..
Therapix Biosciences Ltd.
| Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders|
The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a. The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
| Apoptosis signal-regulating kinase inhibitors|
The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ask1), thus are thus useful in treating ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.. .
Gilead Sciences, Inc.
| Insulin-pramlintide compositions and methods for making and using them|
In alternative embodiments, the invention provides formulations, pharmaceutical compositions, devices and other products of manufacture comprising a therapeutically effective mixture of an insulin and a pramlintide, and methods for making and using them. For example, methods and compositions of the invention are used in the treatment or amelioration of a diabetes, a dementia or alzheimer's disease, any abnormality of blood glucose control, an inability to control blood glucose, an elevation of fasting glucose or impaired fasting glucose (ifg), an abnormality of tolerance to a glucose load or impaired glucose tolerance (igt), a hyperglycemia induced by an illness, a trauma, a medication administration or a form of metabolic, psychological or physical stress, or a hyperglycemia induced by steroids (steroid-induced diabetes), a latent autoimmune diabetes in adults (lada), a postprandial or reactive hypoglycemia or an insulin resistance, a polycystic ovary syndrome (pcos), a ketoacidosis, a gestational diabetes, a hyperkalemia, a cancer or cachexia, a beta blocker overdose, or a jaundice.
Gruppo Biomed Mod
| Compositions and methods for modulating pro-inflammatory immune response|
Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (lilr) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a lilr protein..
The Board Of Regents, The University Of Texas System
| Method and system for prevention and treatment of allergic and inflammatory diseases|
A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..
| Method for treating b cell regulated autoimmune disorders|
The invention relates to a method for treating b-cell regulated autoimmune disorders using compounds that modulate the activity of c-rel.. .
Synta Pharmaceuticals Corporation
| Immune tolerance inducer|
An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ala) or a derivative thereof, or a salt of the 5-ala or the derivative and an iron compound as active ingredients is prepared.
National Center For Child Health And Development
| Oral administration of tocilizumab treatment of autoimmune disease|
The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab.. .
Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy
The present inventors identified a subpopulation of genes induced by type i and type ii ifns in a human submandibular gland (hsg) epithelial cell line. Unexpectedly, it was found that the majority of genes that are highly up-regulated by ifn-α are also highly induced by ifn-γ.
The Johns Hopkins University
Bcr-complex-specific antibodies and methods of using same
This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Heterocyclyl pyrimidine analogues as tyk2 inhibitors
Wherein r, r1, x1 to x5 have the meaning as cited in the description and the claims. Said compounds are useful as tyk2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases.
Which is an inhibitor of spleen tyrosine kinase (syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and b-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.. .
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Concentrated methotrexate solutions
Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune disease.
Salk Institute For Biological Studies
Treatment of il-17 mediated disease by blocking sefir-sefir interactions
A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.
The Cleveland Clinic Foundation
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
A, x, l, y, r, and rn are as defined herein. The invention further relates to the use of the compounds of formula (i) as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, cns disorders, sleeping disorders, or proliferative diseases including cancer.
Novel pyridopyrimidine derivatives and use thereof
The invention provides novel substituted pyridopyrimidines represented by formula i or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ oh kinase family (pi3k) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders..
Cmg Pharmaceutical Co., Ltd.
Crystalline forms of a bruton's tyrosine kinase inhibitor
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Inhibitors of bruton's tyrosine kinase
Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Tropomyosin-related kinase (trk) inhibitors
Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Compositions, methods for treatment, and diagnoses of autoimmunity-related disorders and methods for making such compositions
The present invention provides compositions and methods useful in the diagnosis and treatment of autoimmunity-related disorders, including cancers and other disorders involving angiogenesis, as well as non-cancer disorders involving a dysfunction in the immune system. In some embodiments, the invention described a plasma assay.
Eiger Health Partners, Llc
Sapp-alpha as a biomarker for prediction of inflammatory and autoimmune-related disorders
The subject invention pertains to the use of amyloid precursor protein-alpha (sapp-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders..
University Of South Florida
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Novel amino pyrimidine derivatives
The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with bruton's tyrosine kinase (btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (copd), transplant rejection, cancers e.g.
Tnf -alpha modulating benzimidazoles
A series of benzimidazole derivatives, being potent modulators of human tnfα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.. .
Ucb Biopharma Sprl
Chimeric and humanized anti-histone antibodies
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including psa, psma, steap and psca antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens psa, psma, steap and psca, as well as genetic constructs/vectors and vaccines expressing the sequences.
Inovio Pharmaceuticals, Inc.
A pharmaceutical composition for sublingual, buccal or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.. .
Biotech Tools S.a.
Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity
The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
Ceacam1 mediated protective immunity
The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
The present invention relates to compositions and methods for cancer treatment comprising compounds of formulae i, ii, and iii. In some aspects, the invention relates to the treatment of b-cell lymphoma or other hematopoietic cancers.
Eutropics Pharmaceuticals, Inc.
Popular terms: [SEARCH]
Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence
Follow us on Twitter
This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.